" class="no-js "lang="en-US"> Daniel Nathrath - Medtech Alert
Wednesday, September 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Daniel Nathrath

Daniel Nathrath

About Daniel Nathrath

For 2 decades, Daniel has led the charge to bring transformational technology to new industries. He founded and led several internet startups based in Denmark, Germany, the US, and the UK. After studying law as a Fulbright Scholar at the University of Houston, he earned his Master of Business Administration at the University of Chicago. Daniel worked at Boston Consulting Group before starting his entrepreneurial journey.

Related Story

Appointments

 Ada Expands its Global Leadership Team to Help Drive Company’s Rapid Growth | Pharmtech Focus

Ada Expands its Global Leadership Team to Help Drive Company’s Rapid Growth

July 15 2021

Ada, the global health company, today announces the appointment of digital transformation veterans Gülsah Wilke, […]

Fundraising

 Ada Health Secures £63m Investment to Enhance Assessment Tech | Pharmtech Focus

Ada Health Secures £63m Investment to Enhance Assessment Tech

June 2 2021

Ada Health has secured $90m (£63m) in funding to enhance its health assessment technology. The […]

Fundraising

 Leaps by Bayer Leads USD 90 Million Series B Financing in Digital Health Company Ada Health | Pharmtech Focus

Leaps by Bayer Leads USD 90 Million Series B Financing in Digital Health Company Ada Health

May 28 2021

Leaps by Bayer, the impact investment arm of Bayer AG, today announces that it has […]